Lilly Asia, Qiming, HongShan et al Double Down on Cell Therapy Tech
22 Oct 2024
US$ 19.00
Lilly Asia Ventures, Qiming Venture Partners, HongShan and FreesFund, all existing investors of XellSmart ......
Tag
Biotech
Related Publications
KKR & Co Inc, through its private credit and insurance platforms, has made a cornerstone investment in a A$400 m...
MPCi, Fortune Venture Capital and Shenzhen Capital Group were among returning investors in the recently completed ......
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.